8-K: Acurx Pharmaceuticals Secures $2.3 Million Net Proceeds Through Highly Dilutive Warrant Inducement Agreement

Acurx Pharmaceuticals, Inc. has entered into a warrant inducement agreement, generating approximately $2.3 million in net proceeds by inducing the exercise of existing warrants at a reduced price and issuing new, highly dilutive warrants.

Summary

• Acurx Pharmaceuticals, Inc. (ACXP) entered into a warrant inducement agreement on June 17, 2025, with a holder of existing Series A, B, C, and D warrants.
• The holder exercised 4,445,435 shares of existing warrants for cash at a significantly reduced exercise price of $0.60 per share, down from their original range of $3.25 to $3.26 per share.
• This transaction generated approximately $2.67 million in gross proceeds for the Company.
• In consideration for the exercise, Acurx issued new Series G-1 warrants to purchase 6,223,609 shares and new Series G-2 warrants to purchase 2,667,261 shares, totaling 8,890,870 new warrant shares.
• The new G-1 and G-2 warrants have an exercise price of $0.425 per share.
• H.C. Wainwright & Co., LLC, as the placement agent, will receive a fee equal to 7.0% of the gross proceeds and warrants to purchase 266,726 shares at an exercise price of $0.75 per share.
• The Company expects to receive approximately $2.3 million in net proceeds after deducting offering fees and other expenses.
• The net proceeds are intended for general corporate and working capital purposes.
• The closing of the transactions is expected to occur on or about June 20, 2025.
• The company has agreed to certain restrictions on future equity issuances for 45 days and a prohibition on variable rate transactions for 90 days, with specific exemptions.

Sentiment

Score: 3

Explanation: While the company secured immediate capital, the terms of the financing are highly dilutive, involving a significant reduction in exercise price for existing warrants and the issuance of a large number of new warrants at a very low exercise price. This suggests a distressed capital need and will likely put downward pressure on the stock price due to the increased share count and potential future exercises.

Positives

• Secured approximately $2.3 million in net proceeds, providing immediate capital for general corporate and working capital purposes.
• Successfully induced the exercise of existing warrants, converting potential future capital into immediate cash flow.
• The transaction provides additional potential future capital if the newly issued warrants are exercised.

Negatives

• Existing warrants were exercised at a substantial discount ($0.60 per share) compared to their original exercise prices ($3.25 to $3.26 per share), indicating a significant concession to secure immediate funds.
• The issuance of 8,890,870 new warrants at a low exercise price of $0.425 per share, plus 266,726 warrants to the placement agent, will result in significant future dilution for existing shareholders.
• The exercisability of the Series G-2 warrants (2,667,261 shares) is contingent upon obtaining stockholder approval, introducing uncertainty and potential delays.
• The company agreed to a 45-day restriction on issuing new common stock or equivalents and a 90-day prohibition on variable rate transactions, which could limit future financing flexibility.

Risks

• Dilution Risk: The issuance of new Series G-1 and G-2 warrants, and Wainwright Warrants, will result in significant dilution to existing shareholders if and when exercised.
• Stockholder Approval Risk: The exercisability of the Series G-2 Warrants is contingent upon obtaining stockholder approval, which may not be secured, or may be delayed, impacting the full realization of the capital raise.
• Market Price Volatility: There is no established trading market for the new warrants, limiting their liquidity, and the underlying common stock's value remains subject to market fluctuations.
• Financing Restrictions: The company is restricted from issuing certain equity securities or entering into variable rate transactions for specified periods, which could constrain its ability to raise additional capital quickly if unforeseen needs arise.
• Regulatory Risk: The new warrants and underlying shares were issued under a Section 4(a)(2) exemption and are not registered; their resale is subject to registration or exemption requirements, necessitating the timely filing and effectiveness of a resale registration statement.

Future Outlook

Acurx Pharmaceuticals expects to use the net proceeds from this transaction for general corporate and working capital purposes. The company also plans to file a registration statement for the resale of the new warrant shares and will seek stockholder approval for the exercise of Series G-2 warrants, holding meetings every 90 days if initial approval is not obtained.

Management Comments

• Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a warrant inducement agreement with a certain holder of existing warrants.
• The Company intends to use the net proceeds from the exercise for working capital and general corporate purposes.

Industry Context

Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. Its lead candidate, Ibezapolstat, is advancing to international Phase 3 clinical trials for C. difficile Infection (CDI), a condition designated as an urgent threat by the CDC. This capital raise provides essential funding for ongoing operations and clinical development, which are typically capital-intensive in the biopharmaceutical sector, especially for companies with late-stage drug candidates.

Corporate Governance

Stakeholder Impact

• Shareholders: Significant potential for dilution due to the issuance of a large number of new warrants at a low exercise price and the reduced exercise price for existing warrants. This could negatively impact per-share value.
• Company (Acurx Pharmaceuticals): Receives immediate capital for working capital and general corporate purposes, which is crucial for a late-stage biopharmaceutical company. However, this comes at the cost of substantial dilution and future financing restrictions.
• Warrant Holders (Existing): Benefited from a significantly reduced exercise price for their existing warrants, allowing them to convert at a favorable rate, and received a substantial number of new warrants as an inducement.
• H.C. Wainwright & Co., LLC: Earned a 7.0% fee on gross proceeds and received additional warrants as compensation for their role as placement agent.

Next Steps

• Closing of the warrant inducement transaction is expected on or about June 20, 2025.
• The Company is required to file a registration statement (Form S-3 or S-1) for the resale of the New Warrant Shares within 30 calendar days of June 17, 2025.
• The Company must use commercially reasonable efforts to have the Resale Registration Statement declared effective by the SEC within 60 calendar days (or 90 days if SEC review).
• The Company is obligated to hold an annual or special meeting of stockholders on or prior to 90 days following the Closing Date to obtain Stockholder Approval for the exercise of Series G-2 Warrants.
• If Stockholder Approval for G-2 Warrants is not obtained at the first meeting, the Company shall call a meeting every 90 days thereafter until approval is obtained or the New Warrants are no longer outstanding.

Key Dates

Recommendation

Keywords

Acurx Pharmaceuticals, ACXP, SEC filing, Form 8-K, warrant inducement, capital raise, equity financing, common stock, Series G-1 warrants, Series G-2 warrants, H.C. Wainwright & Co., biopharmaceutical, antibiotics, C. difficile Infection, dilution, working capital